Clinical trials: AMD, open to volunteers
Retinal Degeneration, Retinitis Pigmentosa
Rod and Cone Mediated Function in Retinal Disease
Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal…
- Conditions
- Retinal Degeneration, Retinitis Pigmentosa, Stargardt's Disease
- Trial name
- NCT02617966
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD.
- Trial name
- NCT05986864
- Testing
- SKG0106
- Where
- 9 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Skyline Therapeutics (US) Inc.
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Stargardt Disease, Stargardt Macular Dystrophy
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- DEVOTE (NCT07734064)
- Testing
- ASP2020
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Neovascular (Wet) Age-related Macular Degeneration (AMD)
OCT Angiography in Wet AMD
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2.
- Trial name
- NCT02253030
- Testing
- Optical Coherence Tomography
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Intermediate AMD
MacuTherm Performance Study in Patients With iAMD
The goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors…
- Trial name
- NCT07607496
- Testing
- photothermal therapy
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 240 people
- Sponsor
- OD-OS MacuTherm GmbH
Wet Age Related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- MOJAVE (NCT07816315)
- Testing
- OLN324, Aflibercept
- Volunteers
- 500 people
- Sponsor
- Ollin Biosciences, Inc.
Eye Diseases, Retinitis Pigmentosa
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
- Conditions
- Eye Diseases, Retinitis Pigmentosa, Diabetic Retinopathy, Macular Degeneration
- Trial name
- NCT05147701
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
- Where
- 2 sites in United States, Greece
- Volunteers
- 20 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related (Dry) Macular Degeneration
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old.
- Trial name
- NCT07446582
- Testing
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AI-Spectral
nAMD
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
- Trial name
- NCT06672536
- Testing
- SCT520FF, EYLEA 2 MG
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sinocelltech Ltd.
Age-Related Macular Degeneration, Diabetic Retinopathy
National Eye Institute Biorepository for Retinal Diseases
Background: To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease
- Trial name
- NCT01496625
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Dry Age-Related Macular Degeneration, AMD
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.
- Trial name
- NCT07700147
- Testing
- Transcutaneous Electrical Stimulation
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Nu Eyne Co., Ltd.
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
- Trial name
- NCT07275840
- Testing
- IBI302 8mg dose
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Inclusion Body Myositis, Myotonic Dystrophy 1
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
The planned project is an intervention study to assess the risk of falling after adaptation of an assistive gait devices in patients with the following neuromuscular diseases: Inclusion body myositis, myotonic dystrophy, limb…
- Conditions
- Inclusion Body Myositis, Myotonic Dystrophy 1, Myotonic Dystrophy 2, Facio-Scapulo-Humeral Dystrophy
- Trial name
- Risk of fall (NCT07072676)
- Testing
- Assistive gait devices combined with physiotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LMU Klinikum
Pompe Disease
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD.
- Trial name
- NCT07750990
- Testing
- S-606001, ERT
- Volunteers
- 60 people
- Sponsor
- Shionogi
Neovascular (Wet) Age-Related Macular Degeneration
First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD)
This is a first-in-human clinical trial evaluating the safety and tolerability of BETA-TT8 Ophthalmic Gel in people with wet age-related macular degeneration (AMD).
- Trial name
- BEyOND (NCT07766473)
- Testing
- BETA-TT8 ophthalmic gel 3.8% w/v
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Filamon LTD
Neovascular Age-related Macular Degeneration
Gene Therapy for Wet AMD
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals.
- Trial name
- NCT05611424
- Testing
- FT-003
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Cognitive Performance, Age-Related Macular Degeneration
Lutein, Zeaxathin, and Fish Oil Supplementation
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults.
- Conditions
- Cognitive Performance, Age-Related Macular Degeneration, Bone Loss
- Trial name
- NCT06489873
- Testing
- Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Geographic Atrophy (GA)
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to…
- Trial name
- VIENNA (NCT07230834)
- Testing
- Pozelimab
- Where
- 9 sites in United States, Georgia and 2 more
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals